Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

Clinical trial NCT07087223 · RECRUITING

Trial details

NCT number: NCT07087223
Sponsor: Peking University Cancer Hospital & Institute
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer NSCLC

Start date: 2025-04-08
Primary completion: 2027-04-01
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.